Summary
Understanding how each individual's genetics and physiology influences the pharmaceutical response is crucial to the realization of personalized medicine and the discovery and validation of pharmacogenomic biomarkers is key to its success. However, integration of genotype and phenotype knowledge in medical information systems remains a key challenge. The inability to easily and accurately integrate the results of biomolecular studies with patients' medical records and clinical reports prevents us from realizing the full potential of pharmacogenomic knowledge for both drug development and clinical practice. Herein, we describe approaches using Semantic Web technologies, in which pharmacogenomic knowledge relevant to drug development and medical decision support is represented in such a way that it can be efficiently accessed both by software and human experts. We suggest that this approach increases the utility of data, and that such computational technologies will become an essential part of personalized medicine, alongside diagnostics and pharmaceutical products.
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Future perspective
Personalized medicine involves the customization of therapies based on genetic, environmental and physiological factors to deliver the best possible care to individual patients. In the past decade, there has been a substantial shift in our understanding of factors that influence therapeutic outcomes. This has been driven largely by the increasing availability of large scale profiling technologies, including next generation sequencing and gene expression profiling. One of the prominent applications of molecular profiles in clinical practice is to stratify the patient population in order to identify positive, neutral and negative responders. Widespread use of profiling technologies has become significantly more feasible for inclusion in clinical trials as costs have been decreasing [1] . Indeed, the ability to build and test patient profiles against therapeutic outcomes in clinical trials may increase the number of approved therapies overall, with the resulting drugs and therapies approved for clearly specified segments of the population. Additional benefits for pharmaceutical companies include the opportunity to develop incrementally modified drugs with reduced risk for drug development [2] . While all of these developments promise to change the practice of medicine, a remaining challenge lies in the effective integration of highly heterogeneous data obtained from a variety of sources, and its use in accurate predictive systems for supporting knowledge discovery and personalized clinical decision making.
The role of pharmacogenomics in tailored therapies
In current practice a drug dose is adjusted according to generic factors such as weight, age and kidney and liver function. However, two individuals with the same values for these parameters may respond differently to the same therapy, due primarily to differences at the genetic level that affect either the rate at which the drug is metabolized or the susceptibility of the target to modulation. Pharmacogenomic studies attempt to link genetic variation with differences in the drug responses. The use of an individual's genetic information to select drugs and specify dosages lies at the heart of personalized drug-based therapies. For example, warfarin is one of over a dozen drugs approved by the U.S. Food and Drug markers are provided (table 1) . In the US alone, over 20 million prescriptions of warfarin are written per year to treat chronic anticoagulation indications including atrial fibrillation, deep vein thrombosis, pulmonary embolism and artificial heart valves. Over-or underdosing can have serious consequences: warfarin is one of the leading causes of emergency care and drug-related hospitalization due to adverse drug events [3] . Genetic variations in two key genes have been found to strongly affect the toxicity of warfarin and consequently its initial recommended dose. First, the cytochrome P450 2C9 enzyme (CYP2C9) influences the overall amounts of warfarin in the bloodstream. Second, warfarin's activity depends on the variant of the gene encoding a subunit of its drug target, the enzyme vitamin K epoxide reductase. While the warfarin dosage table is relatively simple to interpret, the inclusion of additional factors and more complex dosing algorithms, which have been demonstrated to improve warfarin dosage [4] [5] [6] , requires a more sophisticated, computer-assisted system for individualizing therapies. Furthermore, it can be expected that clinically relevant pharmacogenomic findings will be discovered for a rapidly growing number of drugs, so that pharmacogenomic considerations will be relevant for not only a few, special therapies, but for a large fraction of commonly prescribed drugs.
As the findings and guidelines for optimizing pharmacotherapy become more complex and more widespread, they are likely to become so overwhelming for clinicians that they are not applied consistently in daily practice. If this occurs, the benefits of treatment optimization based on pharmacogenomic knowledge will not reach patients. To realize the full potential of pharmacogenomics, the use of computer-based decision support systems will become indispensable. The move to more advanced decision support in clinical practice would also make it possible to consider drug-drug interactions that influence drug or target activity.
Semantic Infrastructure for the Biomedical Sciences
In this paper we report on progress toward the development of a global computational infrastructure for pharmacogenomics in the context of personalized medicine. Semantic Web technologies are based on two ideas: resolvable identifiers and machine understandable descriptions. Uniform Resource Identifiers (URI) can be used to identify any entity, whether it is a hospital, a dosage regime, a kind of drug, a kind of genetic variation, or even a clinical report. An example of a URI is that for warfarin (http://bio2rdf.org/drugbank_drugs:DB00682) as defined by Drugbank database, but which is provided by the Bio2RDF project [7] . Entities identified by URIs can be described in terms of their attributes and the relations they hold with other entities. The Resource Description Framework (RDF, [8] ) provides a simple model in which statements are captured using subjectpredicate-object triples, where the predicate indicates a relation between the subject and the object. So, a statement that warfarin is the ingredient of a drug with the brand name Coumadin would be written as:
<http://bio2rdf.org/drugbank_drugs:DB00682> < http://bio2rdf.org/drugbank_ontology:brandName> "Coumadin"
A statement that warfarin (as defined by DrugBank entry) is related to warfarin (DB00682as defined by ChEBI entry 10033) would be written:
<http://bio2rdf.org/drugbank_drugs:DB00682> <http://bio2rdf.org/bio2rdf_resource:xRef> <http://bio2rdf.org/chebi:10033>
Based on such triples, complex networks of interlinked statements can be built. This makes it possible to navigate and aggregate globally distributed data, enabling the transparency and scalability that made the Word Wide Web one the most successful technologies in recent history.
Slightly more sophisticated than RDF is OWL, the Web Ontology Language [9] . OWL is based on formal logics and can be used to capture general rules about the world (such as -every person has two two biological parents‖, -every CYP2C9*2 allele has a thymidine nucleoside at position 430‖). It has been used on many occasions to formally represent pharmacogenomics knowledge so that it becomes possible to answer questions that require automated reasoning [10, 11] .
Linking Open Data
Linked Open Data (LOD) is a set of design principles which make it practical to share machinereadable information on the web. The set of services following these principles has come to be called the Linked Open Data cloud. This cloud is growing exponentially, forming a large, distributed data store collecting cultural, geographic, political, economic, scientific and other information. The distributed nature of these databases enables independent contributions, which is critical to growing knowledge at the scale required to capture the domains intrinsic to solving health care and pharmacology problems. 
Information resources for pharmacogenomics
A number of public domain databases are available that can provide key information relevant for understanding genetic variation and its potential impact on disease and treatment. Of special interest are those curated databases that describe associations between genotypes and phenotypes in humans (some examples are provided in table 2). A large database of curated knowledge and raw data about associations between genes, genetic variants, drug response and disease [13, 14] .
GWAS Central (formerly called HGVbaseG2P)
A database of genome-wide association studies that also provides summaries of study results [15] . SNPedia A wiki-based platform containing information on phenotypes associated with SNP variants, population prevalence of genetic variants and SNP microarrays [16] .
Online Mendelian Inheritance in Man (OMIM)
Information about diseases with Mendelian inheritance, including references to the implicated genes [17] .
dbGaP Results of studies that have investigated the interaction of genotype and phenotype [18] .
GEN2PHEN Knowledge Center
Integrated genotype-to-phenotye data with facilities for data annotation and user feedback [19, 20] .
GET-Evidence A large database of automatically annotated and then manually curated information about the impact of genetic variations [21] .
HuGE Navigator Information on genetic variants, gene-disease associations, gene-gene and gene-environment interactions, and evaluation of genetic tests [22] .
Genetic Association Database (GAD)
Diseases associated with genetic variants [23] .
Genotator An aggregated gene-disease relationship data containing an integrated view over other datasets [24] .
NCBI GeneTests
This resource concerns genetic tests used in diagnostic and genetic counseling [25] .
The Genetic Testing Registry
A database (under development) about genetic markers and tests that enable their clinical exploration [26] .
To create a comprehensive knowledge base about drugs and their pharmacogenomic properties, these data need to be combined with data about approved pharmaceuticals, ongoing clinical trials, drug interactions, clinical guidelines and other kinds of biomedical knowledge including observations that link genotypes to phenotypes. However, the scalable and sustainable integration of data from such a variety of large, complex, distributed and heterogeneous sources has proven to be a challenge. Over the past five years, the development of ontologies to integrate data has emerged as a key technology for addressing the challenge of data integration.
Ontologies and terminologies play a critical role in data integration. They enable users to use well-defined, unambiguous terms to semantically annotate their data, thereby providing the means by which one can query across different datasets which use the same terms. Terminologies and coding systems focus on providing a comprehensive set of terms. By contrast, ontologies are a formal representation for specifying the entities and attributes in a domain of discourse such as pharmacogenomics. When an ontology is expressed in OWL, automatic reasoning can be performed with a variety of free open source tools. Table 3 lists relevant ontologies and terminologies of interest to pharmacogenomics. An ontology built from PharmGKB, and includes biomedical measures and outcomes [29] .
Mutation Impact
Mutation Impact ontology
An ontology designed to represent mutation impacts on protein properties resulting from an information extraction process [30] . 
Extracting knowledge from the pharmacogenomics literature
A substantial amount of pharmacogenomic knowledge is captured in the scientific literature. Unfortunately, this knowledge is expressed in natural language, and is therefore difficult to integrate and use in combination with other structured data resources. To complicate matters, the volume of literature containing facts relevant to pharmacogenomics is large and continuously increasing.
To effectively extract pharmacogenomic facts from the literature, automated methods must be employed. Information extraction techniques such as natural language processing (NLP) as well as statistical models from machine learning can be used to identify entities of pharmacogenomic interest (such as genes, gene variants, drugs and drug responses) and the relations between these entities in unstructured text [45] . After extraction, entities and relations can be normalized with standard dictionaries and ontologies [46, 47] , and encoded in a structured format. Such normalized relations can subsequently be compared to other literature derived relations and to the content of other databases [48] . Furthermore, Semantic Web representations of the extracted normalized relations can be made available to a broader community of researchers, drug developers and medical practitioners.
At present, text collections used for text mining in biomedical research are mostly comprised of Medline abstracts. In the future, information extraction will increasingly be used on full text article collections and will allow a more complete extraction of gene-drug-phenotype relationships from scientific publications, clinical records, or the patent literature.
The use of information extraction techniques in pharmacogenomics resulted, for example, in the creation of tools for the extraction of pharmacogenomic concepts and relationships [49] , the automatic construction of databases, in particular a side effect resource (SIDER) [50] , the completion of pharmacokinetics pathways [51] , the creation of a Pharmacogenomic Relationships Ontology (PHARE) [52] , and the extraction of mutation impacts on protein properties which were used to populate the Mutation Impact Ontology [53] .
Using semantically enabled pharmacogenomics data for personalized clinical decision support
Once all the different components described above are in place and have matured, a powerful system for the creation of decision support systems for personalized pharmacotherapy emerges (Fig. 1) . While clinical decision support systems in the past often suffered from a lack of publicly available, formally represented biomedical knowledge, the translation of the growing wealth of pharmacogenomic findings into rules for clinical decision support is relatively simple. We can conceptualize the ongoing discovery of a gene variant and its impact on medical outcomes as a continuous ‗pharmacogenomic information pipeline' (table 4) . Different stakeholders, datasets and technologies are associated with each level between initial experimental detection of a specific genetic variant (raw preclinical data) and the eventual clinical validation and deployment of genetic data in clinical decision making (established clinical rules that can be implemented in decision support systems). 
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(estimate based on number of FDA product labels containing pharmacogenomic information [55] . This pharmacogenomic information pipeline exhibits a steep decline in the number of genetic variants at the different stages from early clinical research to routine clinical application. It is currently not clear how long the transitions from one level to the next will take on average, and it is possible that the approval / recognition of pharmacogenomic guidelines by official authorities might be a major roadblock towards clinical adoption, especially if large-scale randomized clinical trials are seen as necessary prerequisites for approval. However, Altman et. al recently argued that, given the rapidly decreasing cost of genetic testing and the lack of potential harm relative to established practices, proof of noninferiority might be sufficient for initial implementation of pharmacogenomic guidelines in clinical practice [2] . In such a scenario, the number of pharmacogenomic findings potentially usable in clinical applications could increase rapidly over the coming decade, providing a challenge to clinicians who want to work with the best available evidence. An information infrastructure that makes findings of a specific quality directly available for use in clinical decision support systems, in that case, be critical to the adoption of pharmacogenomics in clinical practice. For example, the OWL ontology language and its automated reasoning functionality can be leveraged to describe subgroups of patients with distinct pharmacogenomic characteristics, and to place individual patients into their appropriate pharmacogenomic groups (exemplified in figure 2 ). 
On the horizon
Several technologies and resources vital to the success of the approach described in this paper are currently under development. While the addition of new pharmacogenomic datasets to the Semantic Web is underway, substantial challenges remain in making the process of conversion sufficiently simple that non-experts can actively participate.
Further work is still required for strengthening the integration of Semantic Web technologies into established IT systems at hospitals, medical practices and pharmaceutical companies [56, 57] .
The work of the HL7 groups for clinical genomics [58] and clinical decision support [59] provide excellent starting points for such an endeavor. The field of pharmacogenomics has grown significantly since the publication of the human genome, and advances in sequencing technology have resulted in an explosion in the amount of genomic data that is now available. As existing data sets are expanded and new sources of information are developed, the challenge of accessing and integrating information will continue to grow.
Semantic Web technologies have already been shown to help address challenges associated with pharmacogenomic data. The next decade will witness a convergence of advances in technology in both the laboratory and in computational infrastructure, which will present exciting opportunities to the field of pharmacogenomics and bring us closer to realizing the vision of personalized medicine.
Executive summary
 Pharmacogenomics has the potential to improve the effectiveness of health care and the development of new therapies.  As pharmacogenomics becomes more complex, the therapies that it enables will depend on advanced decision support systems. These systems will utilize a semantic infrastructure for the biomedical sciences that is now being built.  The datasets required for pharmacogenomics research and application in clinical practice are huge, distributed, heterogeneous and growing. The infrastructure that handles this must lower the cost of accessing and integrating such data.  In order to discover associations between genes, gene variants, drugs, drug response, phenotypes, and diseases, the infrastructure should enable the seamless integration of data among relevant datasets.  To realize the full potential of pharmacogenomics, the fruits of this technology need to be brought all the way from the research environment to the point of routine clinical decision making.
 Semantic Web technologies such as the Resource Description Framework (RDF) and the Web Ontology Language (OWL) are key standards for the creation of such an interoperable information infrastructure for translational, personalized medicine.  Further key datasets for pharmacogenomics will be made available in RDF/OWL formats over the next three years. While challenges remain in integrating these technologies with existing IT systems at hospitals, medical practices and pharmaceutical companies, it is likely that first implementations in these settings will be deployed within the next five years.
